Hemostemix (CVE:HEM) Shares Increase by 25% – Here's the Reason

2 min read | January 26, 2025 09:14 AM GMT | By Team Kalkine Media

Highlights

  • Hemostemix Inc.'s stock price surged by 25% amidst a spike in trading volume.
  • The biotech firm is advancing in stem cell therapy, with its main product, ACP-01, in Phase II trials.
  • Market activity positions Hemostemix with a market cap of C$32.67 million, highlighting investor interest.

Hemostemix Inc. (CVE:HEM) experienced a notable surge in its share price, climbing 25% during mid-day trading on a recent Friday. The trading volume also saw a substantial increase, amounting to 1,444,856 shares, a 111% jump compared to the average session volume. With these movements, the stock settled at C$0.35 after peaking at C$0.36, up from its previous close of C$0.28.

Hemostemix Stock Performance

The stock's performance has been remarkable, with its 50-day simple moving average set at C$0.13 and the 200-day average at C$0.09. Hemostemix now boasts a market capitalization of C$32.67 million, though it carries a price-to-earnings (PE) ratio of -18.75 and a beta of 0.20.

About Hemostemix

Hemostemix Inc., a clinical-stage biotechnology company, is dedicated to the development, manufacturing, and commercialization of blood-derived stem cell therapies. Based in Canada, the company's flagship product, ACP-01, is progressing through Phase II clinical trials aimed at treating vascular diseases, including cardiovascular and peripheral arterial diseases, angina pectoris, and ischemia.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next